BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Genetown

  Glympse Reports Near-Perfect Accuracy with Liquid Biopsy to Predict NASH

  This liquid biopsy uses a panel of peptide biosensors to analyze protein activity from a blood sample and provide actionable readouts of the disease state.

  November 22, 2021

   · 

  4 min read

   · 

  Gail Dutton
• 

  FDA

  Bluebird Spreads Wings After Company Split; REGENXBIO Gets Orphan Nod

  The FDA has granted Cambridge-based bluebird Bio a Priority Review of its Biologics License Application for betibeglogene autotemcel (beti-cel).

  November 22, 2021

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Business

  Twist Bioscience Acquires Abveris to Complement Antibody Capabilities

  Twist Bioscience snapped up in vivo antibody discovery company Abveris Inc. in a deal valued at up to $190 million. The acquisition is expected to bolster Twist’s biopharma antibody capabilities.

  November 22, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Two Chinese Biopharmas Align in $200 Million IO Deal

  CStone forged a licensing agreement with Jiangsu Hengrui Pharmaceuticals that grants the company access to a monoclonal antibody aimed at multiple forms of cancer.

  November 22, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Despite Positive Phase II Data, Connect Derm Drug Faces Tough Market

  Connect Biopharma shares plummeted 55% despite reported positive topline data from its Phase II trial of CBP-201 for adults with moderate-to-severe atopic dermatitis.

  November 22, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Policy

  CDC Authorizes Booster Vaccines for Adults, Highlighting 50-Plus

  The beginning of booster vaccines for adults was in news for a long time. Well, CDS authorized it now, and here’s the reason behind the authorization.

  November 22, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Deals

  Vifor Pharma Doubles Down on Kidney Disease with New Acquisitions

  Switzerland-based Vifor Pharma is acquiring Spain’s Sanifit Therapeutics and another Swiss company, Inositec.

  November 22, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Deals

  Novartis May Have a Suitor for Sandoz; Merck Closes Acceleron Deal

  After indicating it might entertain a sale, Novartis may receive an offer from investment group EQT and the Struengmann family for its generic unit Sandoz.

  November 22, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Pfizer-BioNTech Vaccine Effective Long-Term in Teens; US Vaccine Data in 2076?

  News on COVID-19 vaccine developments and disease studies continue to deliver highs and lows. Here are some of the more recent happenings.

  November 22, 2021

   · 

  6 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Neurocrine Commits Potential $2.6 Billion to Sosei Heptares, Neuropsychiatric Disorders

  Under the strategic collaboration, Neurocrine Biosciences and Sosei Group Corporation will develop and commercialize novel muscarinic receptor agonists to treat the said illnesses.

  November 22, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN